Determine and Confirm the Field Use Protocol for NANOProtect ¿ Non-Toxic Decontaminate for Facilities and Equipment Following Bio Attack

NanoBio Corporation¿s antimicrobial nanoemulsion technology was developed by Dr. James R. Baker at the University of Michigan Medical School over a period of seven years. Reschard was funded by grants for DARPA (Defense Advanced Research Program Agency), which identified a need to have a non-toxic, non-corrosive biodefence decon material that can decontaminated equipment, personnel, structures, and terrain in the event of a bio incident. A series of surfactant lipid nanoemulsions, which have extensive antimicrobial activity and are not toxic to tissues were resultant of this effort. Nanoemulsions are oil in water emulsions that employ droplets that range from 200-800 nanometers. They are composed of detergents, vegetable oil, salt, water, a food grade alcholol and for antrax decontamination a spore germination enhancer. The physical structure of the nanoemulsion contains the surfactants that mediate the antimicrobial activity. The emulsion droplet disrupts nicroorganisms through fusion and the destablixation of the cell membrane leading lysis. In December 1999 the U.S. Army tested a broad spectrum namoemulsion and nine other bio-decontamination technology at Dugway, Utah, against an Anthrax surrogate, Bacillus globigii. Nanoemulsions was one of four technologies that proved effective and the only non-toxic formulation available. Other tests against the vaccine strain of Bacillus anthracis (sterne strain) were conducted by John Hopkins University Applied Physics Lab and by the US Army Institute of Surgical Research. The Phase I SBIR focused on optimization of NanoProtectTM¿s formulations for efficacy against anthracis and on confirmation of product stability. The objective of Phase II SBIR project is to confirm field use and post-use protocols for NanoProtectTM non-toxic decontamination for facilities and equipment following bio-incident. The most efficacious decontamination protocol will be determined through efficacy tests against Bacillus spores and other possible bio-attack pathogens. Test will be conducted on materials typically found in buildings. Extended product stability test will continue in parallel. The commercial application of the technology, NanoProtectTM is that of a nontoxic, safe to humans, bio-decontamination for standby emergency use by first responders. Customers will include federal, state, local governments, and distributors who will sell to corporations and consumers. NanoBio will provide sales and customer support. A subcontractor will manufacture. NanoBio management has significant business experience applicable to the projects required for the commercial success of NanoProtectTM. Nano-Bio is will funded for the commercialization of the products in its¿ production pipeline.